/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | NWBONORTHWEST BIOTHERAPE |
|---|---|
| Last close | no stored close |
| Change % | no stored close |
| Market cap | no stored close |
| P/E | no stored close |
| Revenue | $1M⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenueFromContractWithCustomerExcludingAssessedTax As ofFY ending 2025-12-31 Filing10-K · 0001104659-26-043806 · filed 2026-04-15 Open the filing on EDGAR → |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.
| Rev growth (YoY) | -0.3%FY to 2025-12-31 |
| Net income | $-60162000⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 Filing10-K · 0001104659-26-043806 · filed 2026-04-15 Open the filing on EDGAR →Open the XBRL payload →CiteNORTHWEST BIOTHERAPEUTICS INC (NWBO), us-gaap:NetIncomeLoss: -60,162,000 USD, fiscal year ended 2025-12-31. Form 10-K, accession 0001104659-26-043806, filed 2026-04-15. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001072379/us-gaap/NetIncomeLoss.json |
| Net margin | -4365.9%FY to 2025-12-31 |
| EPS (diluted) | $-0.04⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-12-31 Filing10-K · 0001104659-26-043806 · filed 2026-04-15 Open the filing on EDGAR →Open the XBRL payload →CiteNORTHWEST BIOTHERAPEUTICS INC (NWBO), us-gaap:EarningsPerShareDiluted: -0.04 USD per share, fiscal year ended 2025-12-31. Form 10-K, accession 0001104659-26-043806, filed 2026-04-15. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001072379/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | 4FY to 2025-12-31 |
| Altman Z-ScoreUNVALIDATED | inputs not filed |
| Beneish M-ScoreUNVALIDATED | inputs not filed |
| Next earnings | rep. 08-09 |